Atea Pharmaceuticals Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 55

Employees

  • Stock Symbol
  • AVIR

Stock Symbol

  • Share Price
  • $4.12
  • (As of Monday Closing)

Atea Pharmaceuticals General Information

Description

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 225 Franklin Street
  • Suite 2100
  • Boston, MA 02110
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 225 Franklin Street
  • Suite 2100
  • Boston, MA 02110
  • United States
+1 (857)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Atea Pharmaceuticals Stock Performance

As of 16-Nov-2026, Atea Pharmaceuticals’s stock price is $4.12. Its current market cap is $331M with 80.3M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.12 $4.30 $2.92 - $6.45 $331M 80.3M 281K -$1.95

Atea Pharmaceuticals Financials Summary

As of 30-Sep-2026, Atea Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 198,825 (49,351) (198,027) (338,063)
Revenue 0 0 0 0
EBITDA (171,638) (180,471) (192,534) (163,746)
Net Income (155,402) (158,349) (168,385) (135,956)
Total Assets 200,706 315,218 464,668 594,968
Total Debt 213 843 1,642 2,402
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Atea Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Atea Pharmaceuticals‘s full profile, request access.

Request a free trial

Atea Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Atea Pharmaceuticals‘s full profile, request access.

Request a free trial

Atea Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and c
Drug Discovery
Boston, MA
55 As of 2025

Plymouth Meeting, PA
 

Pittsburgh, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Atea Pharmaceuticals Competitors (16)

One of Atea Pharmaceuticals’s 16 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
CytoAgents Venture Capital-Backed Pittsburgh, PA
Gilead Formerly VC-backed Foster City, CA
Vir Biotechnology Formerly VC-backed San Francisco, CA
Codagenix Venture Capital-Backed Farmingdale, NY
You’re viewing 5 of 16 competitors. Get the full list »

Atea Pharmaceuticals Patents

Atea Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026161597-A1 Advantageous fixed-dose combination treatment for hcv infection Pending 22-Jan-2025
EP-4812173-A1 Compositions and use thereof in treating hepatitis e infections with beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides Pending 10-Jan-2025
WO-2026151964-A1 Compositions and use thereof in treating hepatitis e infections with beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides Pending 10-Jan-2025
WO-2026132293-A1 Diaryl hydantoin compounds and uses thereof Pending 18-Dec-2024
AU-2023276582-A1 Dosage regimens for treatment of dengue infection Pending 26-May-2022 A61K31/7076
To view Atea Pharmaceuticals’s complete patent history, request access »

Atea Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Atea Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Atea Pharmaceuticals‘s full profile, request access.

Request a free trial

Atea Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

36.5 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Atea Pharmaceuticals’s complete esg history, request access »

Atea Pharmaceuticals FAQs

  • When was Atea Pharmaceuticals founded?

    Atea Pharmaceuticals was founded in 2012.

  • Where is Atea Pharmaceuticals headquartered?

    Atea Pharmaceuticals is headquartered in Boston, MA.

  • What is the size of Atea Pharmaceuticals?

    Atea Pharmaceuticals has 55 total employees.

  • What industry is Atea Pharmaceuticals in?

    Atea Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Atea Pharmaceuticals a private or public company?

    Atea Pharmaceuticals is a Public company.

  • What is Atea Pharmaceuticals’s stock symbol?

    The ticker symbol for Atea Pharmaceuticals is AVIR.

  • What is the current stock price of Atea Pharmaceuticals?

    As of 16-Nov-2026 the stock price of Atea Pharmaceuticals is $4.12.

  • What is the current market cap of Atea Pharmaceuticals?

    The current market capitalization of Atea Pharmaceuticals is $331M.

  • Who are Atea Pharmaceuticals’s competitors?

    Inovio Pharmaceuticals, CytoAgents, Gilead, Vir Biotechnology, and Codagenix are some of the 16 competitors of Atea Pharmaceuticals.

  • What is Atea Pharmaceuticals’s annual earnings per share (EPS)?

    Atea Pharmaceuticals’s EPS for 12 months was -$1.95.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process